Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Tris Pharma Inc.

Headquarters: Monmouth Junction, NJ, United States of America
Year Founded: 2000
Status: Private

BioCentury | Sep 18, 2024
Management Tracks

New CEOs at Nura, IMU

Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | May 31, 2024
Data Byte

FDA’s May approvals: an mRNA RSV vax, a bispecific and biosimilars

Moderna’s mResvia is its first mRNA vaccine approved outside COVID-19 pandemic
BioCentury | Jan 24, 2024
Management Tracks

Markison to succeed Heino as Lantheus CEO

Plus: Lisa Olson becomes CEO of Enthera, and updates from Bayer, Neumora, PDS and more
BioCentury | Nov 1, 2023
Management Tracks

Genentech’s Hardy to become CEO at BioMarin

Plus: BMS CEO Boerner appointed chair, and updates from Storm, Amarin, CTRL, Lakewood, Vesica and RS
BioCentury | May 5, 2023
Management Tracks

Walensky resigning as CDC director

Plus: Riva to lead Transgene as CEO and updates from Aerami, Ginkgo and Tris
BioCentury | Apr 30, 2021
Deals

April 29 Quick Takes: Illumina pushes back on EC review of Grail deal, donates tools to global initiative; plus Zhaoke, Sera, Ardelyx, Protalix-Chiesi, Moderna, Phathom, Tris-Park and more

Following last month’s 4-0 vote by the FTC to challenge Illumina’s pending $7.1 billion acquisition of Grail, the company announced that it filed an action in the General Court of
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

BioCentury | Aug 11, 2017
Clinical News

FDA issues CRL to NDA for Vernalis' CCP-08

Items per page:
1 - 10 of 46